Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial
2008

Measles Vaccination in Infants at 4.5 Months

Sample size: 1333 publication 10 minutes Evidence: high

Author Information

Author(s): Martins Cesário L, Garly May-Lill, Balé Carlito, Rodrigues Amabelia, Ravn Henrik, Whittle Hilton C, Lisse Ida M, Aaby Peter

Primary Institution: Bandim Health Project, Guinea-Bissau

Hypothesis

Can early measles vaccination at 4.5 months provide effective protection against measles in infants?

Conclusion

Early vaccination with the Edmonston-Zagreb measles vaccine at 4.5 months significantly reduces the incidence of measles and prevents hospital admissions and mortality.

Supporting Evidence

  • 28% of children had protective maternal antibodies at enrolment.
  • 92% of vaccinated children had measles antibodies at 9 months.
  • Vaccine efficacy against measles infection was 94%.
  • 100% efficacy against hospital admissions for measles.
  • 100% efficacy against measles mortality.

Takeaway

Giving measles vaccine to babies at 4.5 months can help protect them from getting sick before they are old enough for the usual vaccine at 9 months.

Methodology

Randomised clinical trial comparing early measles vaccination at 4.5 months with standard vaccination at 9 months.

Potential Biases

Possible bias in the diagnosis of measles due to lack of blinding regarding vaccination status.

Limitations

The study was an interim analysis and may not capture long-term effects; potential bias in diagnosing measles cases.

Participant Demographics

Infants aged 4.5 months, with a mix of boys and girls from urban Guinea-Bissau.

Statistical Information

P-Value

0.034

Confidence Interval

95% confidence interval 77% to 99%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1136/bmj.a661

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication